Table 3.

Cinacalcet effect on other bone disease medicationsa

ParameterBeforeStudy Month
123456789101112
n5662566256625662566256625662523347854410401435623160
Lanthanum prescription8.811.512.013.114.516.417.618.319.219.419.420.120.5
Lanthanum dosage (mg/d)2293(1228)2336(1236)2424(1197)2416(1212)2409(1225)2368(1228)2511(1213)2631(1241)2675(1292)2719(1273)2698(1263)2693(1237)2748(1264)
Sevelamer prescription73.274.973.673.473.472.671.770.770.469.870.570.670.3
Sevelamer dosage (mg/d)8751(4412)8746(4420)8835(4332)8878(4315)8857(4311)8881(4334)8862(4323)8894(4331)8966(4290)9014(4336)9079(4327)9123(4332)9146(4308)
Lanthanum or sevelamer77.980.579.980.080.580.480.680.580.780.481.181.581.6
Calcium binder prescription383938.338.43938.738.938.438.638.538.538.638.7
Calcium binder dosage (mg)b1625(1276)1602(1277)1647(1237)1667(1249)1675(1265)1701(1304)1691(1315)1715(1345)1749(1377)1766(1351)1796(1384)1823(1430)1825(1460)
    Ca acetate binder dosage (mg/d)b1370(749)1345(809)1393(740)1392(743)1395(751)1401(745)1400(750)1411(761)1420(774)1436(770)1442(787)1459(782)1444(780)
    Ca carbonate binder dosage (mg/d)b1770(1515)1687(1499)1724(1475)1754(1473)1737(1479)1778(1547)1738(1548)1759(1593)1779(1602)1760(1526)1798(1548)1801(1588)1822(1609)
Combination binder prescriptionc21.523.422.322.423.122.923.122.622.922.72323.323.4
Intravenous vitamin D used
    018.217.816.616.616.016.516.616.515.515.015.714.915.4
    0 to ≤8025.024.921.821.821.021.021.219.721.220.119.019.618.9
    >8056.757.361.661.663.062.562.263.863.364.965.365.565.7
Intravenous vitamin D dosage (μg/wk)13.1(12.7)13.3(12.8)13.6(12.7)13.4(12.9)13.4(12.9)13.4(12.8)13.3(12.7)13.5(12.9)13.6(13.0)13.8(13.0)14.0(13.2)14.3(13.5)14.3(13.8)
  • a Data are mean (SD) or percentage of patients.

  • b Elemental calcium dosage; n = number of cinacalcet patients at the end of the month.

  • c Calcium based and non–calcium based.

  • d Percentage of available hemodialysis treatment sessions.